Full Press Release Details
MD Anderson And BridgeBio Pharma Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-to-treat Cancer.
BBIO
MD Anderson And BridgeBio Pharma Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-to-treat Cancer
Key Takeaway: MD Anderson And BridgeBio Pharma Launch Navire Pharma To Develop Targeted Therapy For Patients With Difficult-to-treat Cancer
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis